Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of "Moderate Buy" by Brokerages
Oric Pharmaceuticals (NASDAQ:ORIC) has received a "Moderate Buy" consensus rating from fourteen analysts, with an average one-year target price of $19.90. The company's shares are trading at $9.99, and it recently beat EPS estimates for its last quarter. Insider trading activity shows CEO Jacob Chacko and CFO Dominic Piscitelli selling shares in December.
(ORIC) Volatility Zones as Tactical Triggers
The article provides a detailed analysis of Oric Pharmaceuticals Inc. (NASDAQ: ORIC), highlighting divergent sentiment and a mid-channel oscillation pattern. It outlines three institutional trading strategies tailored for different risk profiles: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. The report also includes multi-timeframe signal analysis, indicating neutral near-term, weak mid-term, and strong long-term signals for ORIC.
Oric Pharmaceuticals Highlights 2025 Milestones at Guggenheim, Targets Phase 3 Prostate Trial in 1H25
Oric Pharmaceuticals (NASDAQ: ORIC) outlined its key development priorities and 2025 milestones at the Guggenheim Biotech Conference, focusing on two lead oncology programs. The company plans to initiate a Phase 3 study for Rinzimetostat in prostate cancer in the first half of 2025, following a Q1 dose-optimization update. Additionally, Oric Pharmaceuticals expects three 20-25 patient readouts for Enozertinib in 2H25, with potential Phase 3 starts soon after, and emphasized its cash runway into H2 2028, supported by a recent $244 million raise.
ORIC: Lead oncology programs progress to phase III with strong funding and promising early data
ORIC Development is advancing two lead oncology programs into phase III trials in 2024, supported by promising early clinical efficacy and safety data. The company is well-funded through 2028, ensuring resources for these critical milestones. This progress stems from insights shared at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals Inc. announced the grant of 173,800 non-qualified stock options and 28,700 restricted stock units to three new non-executive employees on February 2, 2026. These inducement grants were made under the company's 2022 Inducement Equity Incentive Plan, approved by the Compensation Committee, and are subject to vesting schedules tied to continued employment. The company also provided a cautionary note regarding forward-looking statements.
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals, a clinical stage oncology company, announced its participation in three upcoming investor conferences in February 2026. Management will take part in fireside chats and one-on-one meetings at the Guggenheim Emerging Outlook: Biotech Summit, Citi’s 2026 Virtual Oncology Leadership Summit, and Oppenheimer's 36th Annual Healthcare Life Sciences conference. Webcasts of the fireside chats will be available on the company's website.
Three new ORIC hires receive 173,800 options, 28,700 RSUs
ORIC Pharmaceuticals announced inducement equity grants to three new non-executive employees, consisting of 173,800 non-qualified stock options and 28,700 restricted stock units. These grants, made on February 2, 2026, and approved under Nasdaq Rule 5635(c)(4), are subject to vesting schedules over one to three years. The options and RSUs are part of the company's 2022 Inducement Equity Incentive Plan, aimed at employee retention and recruitment.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants to three new non-executive employees, including 173,800 non-qualified stock options and 28,700 restricted stock units. These grants, approved by its Compensation Committee, are compliant with Nasdaq Rule 5635(c)(4) and serve as a material inducement for employment. The grants vest over several years, subject to continued employment.
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals, Inc., a clinical-stage oncology company, announced its participation in three investor conferences in February 2026: Guggenheim Emerging Outlook: Biotech Summit, Citi’s 2026 Virtual Oncology Leadership Summit, and Oppenheimer 36th Annual Healthcare Life Sciences. Management will engage in fireside chats and one-on-one meetings at these events. Webcasts of the fireside chats will be available on the company's website.
Biotech firm ORIC lines up three investor talks this February
ORIC Pharmaceuticals (Nasdaq: ORIC) announced its management will participate in three investor conferences in February 2026, featuring fireside chats and one-on-one meetings. These events include the Guggenheim Emerging Outlook: Biotech Summit, Citi's Virtual Oncology Leadership Summit, and the Oppenheimer 36th Annual Healthcare Life Sciences conference. Webcasts and replays of the fireside chats will be available on the company's investor website.
Oric Pharmaceuticals Approaches Critical Clinical Milestones
Oric Pharmaceuticals is entering a crucial period with key clinical trial initiations for its lead drug candidates. The company plans to start a Phase 3 trial for ORIC-944 in metastatic castration-resistant prostate cancer and registration-enabling studies for ORIC-114 in non-small cell lung cancer this year, with significant data updates anticipated by mid-2026. These advancements and data releases are critical for determining the company's future market position and potential regulatory submissions.
Oric Pharmaceuticals Approaches Critical Clinical Milestones
Oric Pharmaceuticals is entering a critical phase with major clinical trial initiations for its lead drug candidates. The company plans to launch a Phase 3 trial for ORIC-944 in metastatic castration-resistant prostate cancer by mid-2026 and initiate studies for ORIC-114 in non-small cell lung cancer this year, with significant data updates expected by mid-2026 for the latter. These advancements are crucial for the company's progression towards potential commercialization and market entry.
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals announced its participation in three upcoming investor conferences in February 2026: the Guggenheim Emerging Outlook: Biotech Summit, Citi’s 2026 Virtual Oncology Leadership Summit, and Oppenheimer's 36th Annual Healthcare Life Sciences conference. Management will engage in fireside chats and one-on-one meetings at each event. Webcasts of the fireside chats will be available on the company’s website.
Price-Driven Insight from (ORIC) for Rule-Based Strategy
This article provides a price-driven analysis of Oric Pharmaceuticals Inc. (NASDAQ: ORIC), highlighting a weak near-term sentiment but strong mid and long-term outlooks. It details three AI-generated trading strategies with specific entry, target, and stop-loss points tailored for different risk profiles, along with multi-timeframe signal analysis. The report identifies a significant risk-reward setup, targeting a substantial gain against minimal risk.
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals announced its participation in several upcoming investor conferences in February, including the Guggenheim Emerging Outlook: Biotech Summit, Citi’s 2026 Virtual Oncology Leadership Summit, and Oppenheimer 36th Annual Healthcare Life Sciences conference. Management will engage in fireside chats and one-on-one meetings at these events, with webcasts of the discussions available on the company's website. ORIC Pharmaceuticals is a clinical-stage oncology company developing treatments for therapeutic resistance in cancer.
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Up 8.4% - Here's What Happened
Oric Pharmaceuticals (NASDAQ:ORIC) saw its shares increase by 8.4% on Monday, trading up to $11.1250 with 979,744 shares traded. Despite the rise, trading volume was 45% below the average session. Analysts maintain a "Moderate Buy" rating with a consensus price target of $19.90. The company reported a narrower-than-expected quarterly EPS loss and insiders sold shares totaling approximately $496,615 last quarter.
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Down 6.8% - Time to Sell?
Oric Pharmaceuticals (NASDAQ:ORIC) saw its shares fall 6.8% to $11.2850, with trading volume significantly below average. Despite a largely positive analyst sentiment with a "Moderate Buy" rating and an average price target of $19.90, some insiders, including CEO Jacob Chacko, have recently sold shares. The company, focused on developing small molecule therapeutics for solid tumor oncology, has a market cap of $1.11 billion and reported better-than-expected EPS in its last quarterly earnings.
How Investors Are Reacting To ORIC Pharmaceuticals (ORIC) Big-Pharma Partnerships And Cancer Resistance Pipeline
Oric Pharmaceuticals is gaining investor attention due to its cancer resistance therapy pipeline, including Phase 1b candidates ORIC-114 and ORIC-944, and collaborations with Pfizer, Bayer, and Johnson & Johnson. The company's strategy involves focusing on overcoming cancer resistance, backed by early data and partnerships with major pharmaceutical companies. Despite strong year-to-date stock performance and sharpening near-term catalysts like potential Phase 1b readouts, investors also face risks associated with the company's pre-revenue status, ongoing cash burn, and shareholder dilution.
(ORIC) Price Dynamics and Execution-Aware Positioning
The article provides an in-depth analysis of Oric Pharmaceuticals Inc. (NASDAQ: ORIC), highlighting strong sentiment across all horizons and an overweight bias. It outlines institutional trading strategies based on AI models, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The analysis emphasizes an exceptional risk-reward setup targeting a 25.4% gain against a minimal 0.3% risk.
JonesTrading Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $25
JonesTrading analyst Soumit Roy has reiterated a buy rating on Oric Pharmaceuticals (ORIC.US) and increased the target price from $20 to $25. According to TipRanks data, the analyst has a 27.5% success rate and an average return of -12.9% over the past year. This report emphasizes that the information is for informational purposes only and not investment advice.
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Moderate Buy" from Analysts
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) has garnered a "Moderate Buy" consensus rating from analysts, with 11 buy, 2 hold, and 1 sell recommendation, and an average 12-month target price of $19.90. Despite this positive outlook, the company has seen recent insider selling from its CFO and CEO. The stock opened at $12.25 with a market capitalization of $1.19 billion, and institutional investors have been adjusting their positions.
Oric Pharmaceuticals director Heyman sells shares worth $80,430 By Investing.com
Oric Pharmaceuticals director Richard A. Heyman sold 6,700 shares of common stock for $80,430 on January 16, 2026, executed under a pre-arranged Rule 10b5-1 trading plan. The transaction occurred while the stock showed significant momentum but was considered in overbought territory by InvestingPro. Despite the sale, ORIC maintains a strong financial position, though analysts do not expect profitability this year, even with promising clinical trial results for its cancer drug candidates and positive analyst ratings.
Oric Pharmaceuticals director Heyman sells shares worth $80,430
Oric Pharmaceuticals director Richard A. Heyman sold 6,700 shares of common stock for a total of $80,430. The transaction occurred under a pre-arranged Rule 10b5-1 trading plan, with shares sold at a weighted average price of $12.0046. Despite the stock's recent momentum and positive clinical trial results for its cancer drug candidates, analysts do not expect the company to be profitable this year.
Short Interest in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Grows By 19.6%
Short interest in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) increased by 19.6% in December, reaching over 21.4 million shares, representing 23.3% of the company's shares sold short. Despite this, the stock traded up 5.2% to $12.12. Analysts have a "Moderate Buy" rating for ORIC with a consensus price target of $19.90, even as insiders have sold a significant number of shares recently.
ORIC Pharmaceuticals (ORIC) Is Up 32.5% After J&J Lung Cancer Collaboration and Pipeline Update - What's Changed
Oric Pharmaceuticals saw its stock rise 32.5% following updates at the J.P. Morgan Healthcare Conference, including progress on its prostate and lung cancer drugs and a collaboration with Johnson & Johnson for enozertinib in lung cancer. Despite positive clinical data and collaboration news, the company still faces risks related to a lack of revenue, ongoing losses, and the need for future financing, with current stock valuations potentially being optimistic according to some estimates. The article emphasizes that the investment narrative is tied to successful clinical outcomes and funding.
ORIC Pharmaceuticals Stock Pre-Market (-6.1%) : Form 144 Filings Signal Intent to Sell
ORIC Pharmaceuticals (ORIC) stock is down 6.1% in pre-market trading. This decline follows Form 144 filings, which typically indicate an intent by insiders or affiliates to sell restricted securities. The article suggests this news is impacting investor sentiment.
Assessing ORIC Pharmaceuticals (ORIC) Valuation After Fresh Buy Ratings And Johnson & Johnson Collaboration
ORIC Pharmaceuticals (ORIC) has seen increased attention due to new "buy" ratings, positive trial updates for its oncology drugs, and a collaboration with Johnson & Johnson. The stock has experienced significant short-term gains, with a 7-day return of 36.33% and a year-to-date return of 41.00%. Despite these positive developments, the article questions whether the market has already factored in future growth, noting its current price-to-book ratio of 2.8x, which is below peers but slightly above the broader US biotech industry average.
Assessing ORIC Pharmaceuticals (ORIC) Valuation After Fresh Buy Ratings And Johnson & Johnson Collaboration
ORIC Pharmaceuticals (ORIC) stock has seen significant short-term gains following new buy ratings, promising trial updates for its oncology drugs, and a collaboration with Johnson & Johnson. Despite a 2.8x P/B ratio being below the peer average but slightly above the wider US Biotech industry, the company currently reports no revenue and a net loss, suggesting its valuation relies heavily on its balance sheet and pipeline expectations. Investors are prompted to consider if the recent surge fully prices in future growth and to review associated risks.
ORIC Pharmaceuticals provides 2025 operational highlights, upcoming milestones
ORIC Pharmaceuticals has outlined its key operational highlights for 2025 and provided an overview of upcoming milestones. While specific details are not provided in this snippet, the announcement suggests the company is looking ahead with strategic objectives. Investors and stakeholders will likely be watching for further information regarding its pipeline and corporate objectives.
H.C. Wainwright reiterates Buy rating on ORIC Pharmaceuticals stock
H.C. Wainwright has reiterated a Buy rating and a $23 price target for ORIC Pharmaceuticals, citing a "catalyst rich year" in 2026 with upcoming data releases and trial initiations for its drug candidates ORIC-944 and enozertinib. The company has shown strong recent stock momentum, although InvestingPro's Fair Value assessment suggests it may be overvalued. Several other investment firms, including Wells Fargo and Piper Sandler, have also expressed optimism for ORIC's oncology pipeline.
ORIC Pharmaceuticals provides 2025 operational highlights, upcoming milestones
The article from MSN by ORIC Pharmaceuticals provides details on its operational highlights and upcoming milestones for the year 2025. It is expected to cover key achievements, strategic goals, and future developments for the company.
Piper Sandler Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $22
Piper Sandler analyst Kelsey Goodwin has reiterated a buy rating for Oric Pharmaceuticals (ORIC.US), maintaining a target price of $22. According to TipRanks, the analyst has a 67.4% success rate and an average return of 48.6% over the past year. This information is provided for informational purposes only and does not constitute investment advice.
ORIC: Advancing two late-stage oncology drugs with pivotal data and trials expected by 2027
ORIC Pharmaceuticals is progressing two late-stage oncology drugs toward Phase III trials. Rinzimetostat has shown promise in prostate cancer, and enozertinib demonstrated strong intracranial response in lung cancer. Key data readouts and trial initiations for these drugs are anticipated between 2025 and 2027.
Wedbush Reaffirms Outperform Rating for Oric Pharmaceuticals (NASDAQ:ORIC)
Wedbush has reissued an "Outperform" rating for Oric Pharmaceuticals (NASDAQ:ORIC) with a $20 price target, suggesting a significant upside. Analyst sentiment for ORIC is generally positive, with a consensus "Moderate Buy" rating and an average price target of $19.90, despite recent insider stock sales. The biopharmaceutical company is focused on developing therapies to overcome drug resistance in solid tumor oncology.
Wedbush Reiterates Outperform Rating for ORIC at $20 | ORIC Stoc
Wedbush has reiterated its Outperform rating for ORIC Pharmaceuticals with a price target of $20. This comes amidst consistent analyst support, with several other firms also initiating or maintaining positive ratings and price targets for ORIC in late 2025 and early 2026. ORIC Pharmaceuticals, a clinical-stage biopharmaceutical company focused on cancer therapies, currently has an average target price of $21.00 from 13 analysts, implying a significant upside from its current price.
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
ORIC Pharmaceuticals announced operational highlights for 2025, detailing progress in its rinzimetostat and enozertinib programs, including potential best-in-class efficacy and safety data. The company extended its cash runway into the second half of 2028 after raising $244 million and anticipates multiple clinical data readouts and initiations of registrational trials in 2026. These advancements position ORIC to move its pipeline towards commercialization.
(ORIC) as a Liquidity Pulse for Institutional Tactics
This article provides an AI-driven analysis of Oric Pharmaceuticals Inc. (NASDAQ: ORIC), highlighting strong sentiment across all time horizons and an exceptional 84.3:1 risk-reward setup. It details institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels. The analysis aims to help institutional investors optimize position sizing and minimize drawdown risk.
ORIC Pharmaceuticals reports progress on cancer drug candidates
ORIC Pharmaceuticals announced promising clinical trial results for two lead cancer drug candidates, rinzimetostat and enozertinib, highlighting significant progress in metastatic castration-resistant prostate cancer and non-small cell lung cancer, respectively. The company also strengthened its financial position, raising $244 million and expecting funds to last into the second half of 2028. Analysts have initiated or raised ratings, reflecting growing interest in ORIC's oncology programs.
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
ORIC Pharmaceuticals announced its operational highlights for 2025, detailing progress in its clinical-stage oncology programs. Key achievements include promising Phase 1b data for rinzimetostat in metastatic castration-resistant prostate cancer and enozertinib in NSCLC with EGFR exon 20 and PACC mutations. The company also strengthened its financial position with a $244 million raise, extending its cash runway into the second half of 2028.
Prostate and lung cancer drugs move toward late-stage human trials in 2026
ORIC Pharmaceuticals provided operational highlights for 2025 and anticipated milestones for 2026, announcing strong clinical progress for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC) and enozertinib in non-small cell lung cancer (NSCLC). The company plans to initiate a Phase 3 trial for rinzimetostat in the first half of 2026 and expects multiple clinical data readouts for both drugs throughout the year. ORIC also reported $413 million in cash and investments, extending its operational runway into the second half of 2028.
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
ORIC Pharmaceuticals announced operational highlights for 2025, detailing progress with rinzimetostat and enozertinib, both showing potential best-in-class efficacy and safety in prostate and lung cancers, respectively. The company also strengthened its financial position, raising $244 million and extending its cash runway into the second half of 2028. ORIC anticipates multiple clinical data readouts and the initiation of registrational trials in 2026 for both programs.
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
ORIC Pharmaceuticals announced key operational highlights for 2025 and upcoming milestones, including promising Phase 1b data for rinzimetostat in mCRPC and enozertinib in NSCLC. The company also strengthened its financial position, raising $244 million to extend its cash runway into the second half of 2028. ORIC anticipates multiple clinical data readouts in 2026 and the initiation of registrational trials for its lead programs.
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 7.8% Higher - Should You Buy?
Oric Pharmaceuticals (NASDAQ:ORIC) saw its stock rise 7.8% to $9.11 on Friday with light trading volume. Analysts mostly have a "Moderate Buy" rating with an average price target of $19.90, despite the company having negative earnings and recent insider selling. The company is a clinical-stage biopharmaceutical firm focused on developing small molecule therapeutics for solid tumor oncology.
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded by Piper Sandler to Strong-Buy Rating
Piper Sandler has upgraded Oric Pharmaceuticals (NASDAQ:ORIC) to a "strong-buy" rating. Despite a consensus "Moderate Buy" rating among analysts with a target price of $19.90, the stock's recent open was $8.45. Insider selling has been noted, with 54,814 shares sold in the last 90 days, though insiders still retain 6.82% ownership.
Piper Sandler initiates ORIC Pharmaceuticals stock with Overweight rating
Piper Sandler has initiated coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with an Overweight rating and a $22.00 price target, citing a potential 170% upside. The firm highlighted ORIC-944 as a "potential best-in-class PRC2 inhibitor" with a clinical update expected in Q1 2026, which could be a significant "value creation event." ORIC's strong balance sheet, with more cash than debt and a high current ratio, is seen as supportive of its development plans, despite the company not being expected to be profitable this year.
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
ORIC Pharmaceuticals, Inc. announced that its CEO, Jacob M. Chacko, M.D., will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:45 a.m. PT. The clinical-stage oncology company is focused on developing treatments for therapeutic resistance, with pipeline candidates including ORIC-944 for prostate cancer and enozertinib (ORIC-114) for various genetically defined cancers. A live webcast and replay of the presentation will be available on the company's website.
Piper Sandler Initiates Coverage on ORIC with Overweight Rating and $22 PT | ORIC Stock News
Piper Sandler has initiated coverage on ORIC Pharmaceuticals (ORIC) with an "Overweight" rating and a price target of $22. This follows a series of recent analyst actions reflecting varied perspectives on the company, which is a clinical-stage biopharmaceutical firm focused on therapies for cancer resistance mechanisms. Wall Street analysts generally forecast an "Outperform" status for ORIC, with an average target price of $20.92, implying significant upside from its current price.
Piper Sandler initiates ORIC Pharmaceuticals stock with Overweight rating By Investing.com
Piper Sandler initiated coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with an Overweight rating and a $22.00 price target, citing the potential of ORIC-944 as a "best-in-class PRC2 inhibitor" and a key combination partner for prostate cancer treatments. The firm expects a clinical update in Q1 2026 for ORIC-944 to be a "value creation event." Despite a promising pipeline, the company is not expected to be profitable this year.
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
ORIC Pharmaceuticals, Inc. announced that its CEO, Jacob M. Chacko, M.D., will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 9:45 a.m. PT. A live webcast of the presentation will be available on the company's website, with a replay accessible for 90 days. ORIC Pharmaceuticals is a clinical-stage oncology company focusing on developing treatments to overcome therapeutic resistance in cancer.
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
ORIC Pharmaceuticals announced that CEO Jacob M. Chacko, M.D., will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:45 a.m. PT. A live webcast and replay will be available through the company's investor website. ORIC Pharmaceuticals is a clinical-stage oncology company developing treatments like ORIC-944 for prostate cancer and enozertinib for genetically defined cancers.
